Showing results (221-230 of 239) with videos related to

Sort By:
Pageof 24
International Journal for Parasitology. Drugs and Drug Resistance|January 23, 2019
Screening of a PDE-focused library identifies imidazoles with in vitro and in vivo antischistosomal activitySanaa S Botros, Samia William, Abdel-Nasser A Sabra, et al.
Leukemia Research|November 25, 2015
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemiaMaría-Belén Vidriales, Estefanía Pérez-López, Carlota Pegenaute, et al.
Blood|August 2, 2008
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBruno Paiva, Maria-Belén Vidriales, Jorge Cerveró, et al.
Blood|September 17, 2009
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patientsBruno Paiva, Maria-Belén Vidriales, Gema Mateo, et al.
Elife|September 9, 2024
Allosteric modulation of the CXCR4:CXCL12 axis by targeting receptor nanoclustering via the TMV-TMVI domainEva M García-Cuesta, Pablo Martínez, Karthik Selvaraju, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 19, 2025
Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell TransplantationBorja Puertas, Elena Alejo, José J Pérez-Morán, et al.
Blood|April 13, 2016
Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosisBruno Paiva, Joaquin Martinez-Lopez, Luis A Corchete, et al.
British Journal of Haematology|June 18, 2026
Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survivalBorja Puertas, Irene Padilla, Elena Alejo, et al.
Journal of Hematology & Oncology|April 13, 2017
Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemiaMiguel Quijada-Álamo, María Hernández-Sánchez, Cristina Robledo, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2021
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM ExperiencePaula Rodriguez-Otero, Maialen Sirvent, Ana Pilar González-Rodríguez, et al.
Pageof 24